Key Takeaways
- Punjab’s health authorities have suspended the supply of Glycosting injection.
- The affected batch, BBG11, contains glycopyrrolate 0.5mg and neostigmine methylsulfate 2.5mg.
- The suspension is precautionary while further investigation is carried out.
Punjab’s health authorities have ordered an immediate halt to the release, distribution, and supply of a batch of Glycosting injection, following reports of suspected adverse drug reactions. The Directorate of Drug Control, Punjab, issued the medicine stoppage alert under Alert No. 125/2026.
The affected product is Glycosting 1ml injection, which contains glycopyrrolate 0.5mg and neostigmine methylsulfate 2.5mg. The alert identifies the affected batch as BBG11, with an expiry date of January 2028. The Provincial Quality Control Board has directed that the medicine be stopped as a precaution while further investigation and regulatory action are carried out.
Healthcare facilities across Punjab have reported suspected adverse drug reactions, including severe bradycardia, or an abnormally slow heart rate, associated with the use of the affected batch. Manufacturers and market authorization holders have been instructed to immediately stop the release, distribution, and supply of the affected batch and submit relevant manufacturing, quality-control, distribution, complaint, and pharmacovigilance records.
Pharmacies, wholesalers, distributors, and healthcare facilities have also been instructed to stop administering, dispensing, selling, supplying, or otherwise distributing the batch and to quarantine any remaining stock. Healthcare facilities have been advised to report inventory and consumption records to the relevant drug inspector.
Patients and consumers have also been advised not to use or receive the affected batch as a precaution. The Provincial Quality Control Board is conducting a thorough investigation to determine the cause of the suspected adverse reactions and to ensure the safety of the public.
The suspension of the Glycosting injection supply is a precautionary measure to protect the health and safety of the public. The Provincial Quality Control Board will provide updates on the investigation and any further actions that may be necessary.
Healthcare professionals and the public are encouraged to remain vigilant and report any suspected adverse reactions to the relevant authorities. The Provincial Quality Control Board will continue to monitor the situation and take appropriate action to ensure the safety and well-being of the public.
